Satellos Bioscience Inc. (NASDAQ:MSLE) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Satellos Bioscience Inc. (NASDAQ:MSLE) has been assigned an average rating of “Moderate Buy” from the six ratings firms that are covering the stock, Marketbeat reports. One analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and four have assigned a buy recommendation to the company. The average 12-month target price among analysts that have issued ratings on the stock in the last year is $18.00.

A number of analysts have weighed in on the company. Guggenheim initiated coverage on Satellos Bioscience in a research note on Tuesday. They issued a “buy” rating and a $23.00 target price on the stock. Cantor Fitzgerald assumed coverage on shares of Satellos Bioscience in a report on Wednesday, March 11th. They issued an “overweight” rating on the stock. Leerink Partners began coverage on shares of Satellos Bioscience in a research note on Monday, April 6th. They issued an “outperform” rating and a $20.00 price target on the stock. HC Wainwright lifted their price objective on shares of Satellos Bioscience to $11.00 and gave the company a “buy” rating in a report on Monday, March 30th. Finally, Wall Street Zen cut shares of Satellos Bioscience from a “sell” rating to a “strong sell” rating in a research report on Saturday, April 25th.

Satellos Bioscience Stock Performance

Shares of NASDAQ MSLE opened at $7.95 on Friday. The business has a 50 day simple moving average of $8.32. Satellos Bioscience has a fifty-two week low of $4.53 and a fifty-two week high of $13.39. The stock has a market capitalization of $165.60 million, a P/E ratio of -5.13 and a beta of 1.37.

Satellos Bioscience (NASDAQ:MSLE) last posted its quarterly earnings data on Friday, March 27th. The company reported ($0.47) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.11). Research analysts expect that Satellos Bioscience will post -2.04 EPS for the current year.

Satellos Bioscience Company Profile

Satellos Bioscience Inc is a regenerative medicine company dedicated to developing novel therapeutics which stimulate or restore muscle regeneration in severe disorders. The company’s lead program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy. Satellos Bioscience Inc, formerly known as iCo Therapeutics Inc, is based in Toronto, Ontario.